Alder Biopharmaceuticals Inc (ALDR) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $-0.76 earnings per share for the quarter, missing the analyst consensus estimate by $-0.04. Analysts had a consensus of $-0.72. Analysts expectations of $.14 million. During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on Alder Biopharmaceuticals Inc. Alder Biopharmaceuticals Inc was Resumed by Wells Fargo to “Outperform” on Apr 21, 2016. Brean Capital Initiated Alder Biopharmaceuticals Inc on Apr 20, 2016 to “Buy”, Price Target of the shares are set at $45.
Alder Biopharmaceuticals Inc opened for trading at $27.7 and hit $28.76 on the upside on Wednesday, eventually ending the session at $28.13, with a gain of 0.97% or 0.27 points. The heightened volatility saw the trading volume jump to 8,06,936 shares. Company has a market cap of $1,231 M.
In a different news, on Apr 18, 2016, Randall C Schatzman (President and CEO) sold 30,000 shares at $28.07 per share price. According to the SEC, on Jan 6, 2016, Mark James Litton (Chief Business Officer) sold 25,000 shares at $31.52 per share price. On Jan 6, 2016, John A Latham (Chief Scientific Officer) sold 10,000 shares at $31.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company discovers develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy as well as speed of onset and durability of therapeutic response. The Company’s pipeline includes ALD403 Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6) and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH) and is being developed for the treatment of Cushing’s disease.